Does exogenous coenzyme Q10 affect aerobic capacity in endurance athletes?

International Journal of Sport Nutrition and Exercise Metabolism

Volumn 7, Issue 3, 1997, Pages 197-206

  Weston, Shane B ^a,b   Zhou, Shi ^a   Weatherby, Robert P ^a   Robson, Susanne J ^a  

^a SOUTHERN CROSS UNIVERSITY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

CoQ10 supplementation; Oxygen uptake; Plasma CoQ10 levels

Indexed keywords

DRUG DERIVATIVE; LACTIC ACID DERIVATIVE; UBIDECARENONE; UBIQUINONE;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXERCISE; EXERCISE TOLERANCE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; ORAL DRUG ADMINISTRATION; OXYGEN CONSUMPTION; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SPORT; AEROBIC CAPACITY; ATHLETE; CYCLING; ENDURANCE; EXERCISE TEST; EXHAUSTION; HEART RATE; HUMAN EXPERIMENT; LACTATE BLOOD LEVEL; NORMAL HUMAN; SUPPLEMENTATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; DOUBLE-BLIND METHOD; EXERCISE; EXERCISE TOLERANCE; HUMANS; LACTATES; MALE; OXYGEN CONSUMPTION; SPORTS; UBIQUINONE;

EID: 0030612516     PISSN: 10501606     EISSN: None     Source Type: Journal    
DOI: 10.1123/ijsn.7.3.197     Document Type: Article

References (34)

1. 2max and diastolic function in athletes. In Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers and G. Littarru (Eds.), Amsterdam: Elsevier, 1991, pp. 525-533.
2. Beckman Instruments. Chemistry Information Manual - Synchron Clinical Systems. Brea, CA: Beckman Diagnostic Systems Group, 1992.
3. 31P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies. Neurology 42:1203-1208, 1992.
4. 2max, and lipid peroxidation in trained cyclists. Int. J. Sport Nutr. 1:353-365, 1991.
5. Cheng, B., H. Kuipers, A. Snyder, A. Keizer, A. Jeukendrup, and M. Hesselink. A new approach for the determination of ventilatory and lactate thresholds. Int. J. Sports Med. 13:518-522, 1992.
6. Cleary, J., D. Mohr, M. Adams, D. Celermajer, and R. Stocker. Plasma and LDL levels of major lipophilic antioxidants are similar in patients with advanced atherosclerosis and age-matched controls. Free Rad. Res. (in press).
7. 10 in essential hypertension. Mol. Aspects Med. 15:S257-S263, 1994.
8. 10 treatment in high level athletes. In Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers, G. Littarru, and T. Yamagami (Eds.). Amsterdam: Elsevier, 1991, pp. 513-520.
9. 10. Proc. Nat. Acad. Sci. USA 82:901-904, 1985.
10. 10 administration on pulmonary function and exercise performance in patients with chronic lung diseases. Clin. Invest. 71:5162-5166, 1993.
11. 10: A new drug for cardiovascular disease. J. Clin. Pharmacol. 30:596-608, 1990.
12. 10 in plasma. J. Chromatogr. 593:217-226, 1992.
13. Guerra, G., E. Ballardini, S. Lippa, A. Oradei, and G. Littarru. Effect of the administration of ubidecarenone over the maximum consumption of oxygen and on the physical performance in a group of young cyclists. Med. Sport. 40:359-364, 1987.
14. Harrison, M., M. Graveney, and L. Cochrane. Some sources of error in the calculation of relative change in plasma volume. Eur. J. Appl. Physiol. 50:13-21, 1982.
15. Kindermann, W., G. Simon, and J. Keul. The significance of the aerobic-anaerobic transition for the determination of work load intensities during endurance training. Eur. J. Appl. Physiol. 42:25-34, 1979.
16. 10: Blood levels and metabolic demand. Int. J. Tissue React. 12:145-148, 1990.
17. Lücker, P., N. Wetzelsberger, G. Hemmings, and D. Rehn. Pharmacokinetics of coenzyme ubidicarenone in healthy volunteers. In Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers and Y. Yamamura (Eds.). Amsterdam: Eisevier, 1984, pp. 143-151.
18. Mathews, C.K., and K.E. van Holde. Biochemistry. Redwood City: Benjamin/Cummings, 1990.
19. 10 against the attack of phospholipase to myocardial membrane. Drug Res. 36:187-189, 1986.
20. 10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid perodixation. Biochim. Biophys. Acta. 1126:247-254, 1992.
21. 10. Neurology 36:45-53, 1986.
22. 10 in Kearns-Sayre syndrome. Neurology 35:372-377, 1985.
23. 10 on ischemia and reperfusion of the isolated perfused rat heart. J. Mol. Cell. Cardiol. 13:65-74, 1981.
24. Orr, G., H. Green, R. Hughson, and G. Bennett. A computer linear regression model to determine ventilatory anaerobic threshold. J. Appl. Physiol. 52:1349-1352, 1982.
25. Poole, D.C., and G.A. Gaesser. Responses of ventilatory and lactate thresholds to continuous and interval training. J. Appl. Physiol. 58:1115-1121, 1985.
26. 10 on the exercise tolerance of middle-aged, untrained men. Int. J. Sports Med. 16:421-427, 1995.
27. 10 on exercise performance. Med. Sci. Sports Exerc. 22:S87, 1990.
28. Snider, I., T Bazzarre, S. Murdoch, and A. Goldfarb. Effects of coenzyme athletic performance system as an ergogenic aid on endurance performance to exhaustion. Int. J. Sport Nutr. 2:272-286, 1992.
29. Tan, M., E. Wilmshurst, R. Gleason, and J. Soeldner. The effect of posture upon the composition and volume of the blood in man. New Engl. J. Med. 289:416-419, 1973.
30. 10 in man. Int. J. Clin. Pharmacol. Ther. Toxicol. 24:536-541, 1986.
31. Wasserman, K. The anaerobic threshold measurement to evaluate exercise performance. Am. Rev. Resp. Dis. 129:5535-540, 1984.
32. 10 in human blood plasma. Int. J. Vitant. Nutr. Res. 64:311-315, 1994.
33. 10 on physical work capacity in athletes, sedentary people, and patients with mitochondrial disease. In Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers, G. Littarru, and T. Yamagami (Eds.). Amsterdam: Elsevier, 1991, pp. 541-545.
34. 10) on the metabolic response to work. J. Sports Med. Phys. Fitness 29:57-62, 1989.